Effects of formoterol (Oxis® Turbuhaler®) and ipratropium on exercise capacity in patients with COPD

Liesker, J.J.W.; Velde, Veerle Van de; Meysman, Marc; Vincken, Walter; Wollmer, Per; Hansson, Lennart; Kerstjens, Huib A. M.; Qvint, U; Pauwels, R.

doi:10.1053/rmed.2001.1335

Cited by 38 publications

(30 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Europe, studies have shown formoterol to have beneficial effects at dosages of 4.5, 9 and 18 μg twice daily (bid) in patients with COPD (9,10). However, the effects of formoterol on lung functions and symptoms have never been investigated in Japanese patients with COPD.…”

Section: Copd Is a Disease State Characterized By The Presence Of Chrmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Formoterol in Japanese Patients with COPD

et al. 2008

View full text Add to dashboard Cite

Section: Copd Is a Disease State Characterized By The Presence Of Chrmentioning

confidence: 99%

“…assuming that the standard deviation of log-transformed FEV1 was 0.10 (9). Allowing for withdrawals, a total of 37 patients was the target sample size for randomization in this study.…”

Section: F I G U R E 1 F L O W D I a G R A M O F P A T I E N T D I mentioning

confidence: 99%

Efficacy and Safety of Formoterol in Japanese Patients with COPD

et al. 2008

View full text Add to dashboard Cite

“…16,17 Furthermore, these effects seem to be dose dependent; formoterol improves lung function parameters with a positive dose-response relationship and exercise capacity with a negative relationship, probably because increased unevenness in ventilation-perfusion ratio at higher doses limits exercise capacity. 29 This study had several limitations. First, the relatively small sample size and the short period between dosing and measurements likely increased the threshold for some changes (eg, VAS results) achieving significance after the administration of formoterol.…”

Section: Discussionmentioning

confidence: 93%

Effects of Formoterol Inhaled Dry Powder on Exercise Performance in Chronic Obstructive Pulmonary Disease: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Crossover Study

Fuso¹,

Incalzi²,

Basso³

et al. 2003

Current Therapeutic Research

View full text Add to dashboard Cite

Background: Inhaled bronchodilators commonly are used to reduce the work of breathing in patients with chronic obstructive pulmonary disease (COPD). The effects of bronchodilators are assessed in terms of symptom relief and/or improvements in spirometric indices. However, disability in COPD patients also is related to determinants such as exercise tolerance, which cannot be predicted on the basis of respiratory function. The effect of bronchodilators, such as inhaled beta 2 -agonists, on exercise performance of COPD patients needs to be tested.Objective: This study investigated the effects of formoterol inhaled dry powder on exercise performance assessed using the shuttle walking test (SWT) in patients with mild to moderate COPD.Methods: Patients having COPD with mild to moderate airway obstruction performed a pulmonary function test and an SWT before and after inhalation, on 2 consecutive days, of formoterol 12 µg or placebo, given by dry powder inhaler, according to a double-blind, placebo-controlled, crossover study design. Breathlessness was measured using the Borg scale (BS) and a visual analog scale at baseline and after an SWT.Results: Twenty patients (15 men, 5 women; mean [SD] age, 65.95 [8.32] years) were included in the study. Forced expiratory volume in 1 second (FEV 1 ) (P ϭ 0.009), forced mid-expiratory flow (FEF 25-75 ) (P ϭ 0.011), and SWT (P ϭ 0.005) improved significantly more with formoterol than placebo. Breathlessness decreased with formoterol, but the difference compared with placebo was statistically significant only when measured using the BS (P ϭ 0.023). In the pooled placebo and formoterol tests, changes in the SWT were unrelated to changes in FEV 1 (r ϭ 0.18) and in FEF 25-75 (r ϭ 0.31). CURRENT THERAPEUTIC RESEARCH Conclusions:The results of this study showed that formoterol inhaled dry powder significantly improved exercise performance in patients with COPD and that this effect was at least partially independent of achieved bronchodilation. A larger cohort of patients should be studied and a more comprehensive protocol performed to verify whether the increase in exercise tolerance after administration of formoterol is related to a decrease in expiratory flow limitation during exercise and/or to systemic effects of the drug. Another issue to be clarified is whether the improvement in exercise capacity can significantly decrease disability in patients with severe COPD. (Curr Ther Res Clin Exp. 2003;64:317-326)

show abstract

“…Long-acting beta-agonists such as salmeterol and formoterol have been shown to decrease resting and dynamic hyperinflation and increase exercise performance [120][121][122][123][124], although this improvement did not always reach clinical significance. Indacaterol, tiotropium, glycopyrronium bromide and aclidinium bromide also showed their ability to positively impact hyperinflation and improve exercise capacity [92,[125][126][127][128][129][130][131][132][133].…”

Section: Treatmentmentioning

confidence: 99%

The clinical relevance of the emphysema-hyperinflated phenotype in COPD

et al. 2015

View full text Add to dashboard Cite

The classification of chronic pulmonary obstructive disease (COPD) into clinical and pathophysiological subsets is not new, but increasing data is available on the relation of these different phenotypes to clinically meaningful outcomes. This review focuses on the "emphysema-hyperinflation" (EH) phenotype, which is characterised by a prominent loss of lung elastic recoil and hyperinflation burden that translates into marked exercise intolerance and a heightened sense of dyspnoea. Although no single genetic profile has been associated with the EH phenotype, recent data have shown that certain single nucleotide polymorphisms, such as DNAH5, appear to have an effect on the preferential development of hyperinflation in smokers. Static and dynamic hyperinflation are hallmarks of the EH phenotype, and abnormal increases in resting lung function indices such as total lung capacity (TLC), functional residual capacity (FRC) and inspiratory to TLC ratio (IC/TLC) seem more associated with the clinical EH phenotype than others markers of gas trapping. An increased level of dyspnoea on exertion and exercise intolerance are also characteristic of the EH presentation and are likely related in part to critical mechanical constraints imposed on tidal volume expansion in situations where ventilatory demands are increased, but also possibly on cardiac and hemodynamic anomalies related to emphysema and hyperinflation. Importantly, the clinical relevance of the EH phenotype is underlined by the finding that indices of hyperinflation such as IC/TLC and residual volume (RV) can be used as independent predictors of mortality in patients with COPD. Treatment of patients with the EH phenotype should primarily focus on smoking cessation and maximal bronchodilator therapy. New long-acting combined bronchodilators options provide clinicians with safe and effective ways to address the hyperinflation issue in this population. Pulmonary rehabilitation also has a positive impact on exercise tolerance, quality of life and hyperinflation, and should be routinely considered in patients with EH presentation that remain symptomatic despite optimal treatment, whereas as lung volume reduction techniques should be reserved for highly selected patients.

show abstract

Effects of formoterol (Oxis® Turbuhaler®) and ipratropium on exercise capacity in patients with COPD

Cited by 38 publications

References 31 publications

Efficacy and Safety of Formoterol in Japanese Patients with COPD

Efficacy and Safety of Formoterol in Japanese Patients with COPD

Effects of Formoterol Inhaled Dry Powder on Exercise Performance in Chronic Obstructive Pulmonary Disease: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Crossover Study

The clinical relevance of the emphysema-hyperinflated phenotype in COPD

Contact Info

Product

Resources

About